logo
  

McCormick Boosts FY21 Outlook - Quick Facts

While reporting financial results for the second quarter on Thursday, flavor maker McCormick & Co., Inc. (MKC) raised its earnings, adjusted earnings and sales growth guidance for the full year 2021, based on strong year-to-date results and robust operating momentum.

For fiscal 2021, the company now projects earnings in a range of $2.83 to $2.88 per share and adjusted earnings in a range of $3.00 to $3.05 per share on sales growth of 11 to 13 percent, which in constant currency is a 8 to 9 percent.

Previously, the company expected earnings in a range of $2.77 to $2.82 per share and adjusted earnings in a range of $2.97 to $3.02 per share on sales growth of 8 to 10 percent or 6 to 8 percent in constant currency.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.00 per share on sales growth of 9.30 percent to $6.12 billion for the year. Analysts' estimates typically exclude special items.

The company noted that it now expects a three-percentage point favorable impact from currency rates on sales and reaffirms the two-percentage point favorable impact from currency on adjusted operating income and adjusted earnings per share.

McCormick said it is well positioned for continued growth through the combination of its alignment with these consumer trends, the breadth and reach of its flavor portfolio and its effective growth strategies.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT